Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Plaque Erosion: A New in Vivo Diagnosis and Paradigm Shift in the Treatment of Patients With Acute Coronary Syndrome

X
Trial Profile

Plaque Erosion: A New in Vivo Diagnosis and Paradigm Shift in the Treatment of Patients With Acute Coronary Syndrome

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 17 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aspirin (Primary) ; Enoxaparin sodium (Primary) ; Heparin (Primary) ; Ticagrelor (Primary)
  • Indications Acute coronary syndromes
  • Focus Proof of concept; Therapeutic Use
  • Acronyms EROSION
  • Most Recent Events

    • 06 May 2022 Results of an analysis assessed the evolution of hemodynamic parameters on the plaque erosion site in conservatively treated patients published in the International Journal of Cardiology
    • 28 Oct 2016 New trial record
    • 30 Aug 2016 Primary endpoint (Reduction of thrombus burden by OCT) has been met, according to results published in the European Heart Journal.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top